Regeneron Pharmaceuticals Dirección

Dirección controles de criterios 0/4

Información clave

Leonard Schleifer

Chief Executive Officer (CEO)

US$7.0m

Compensación total

Porcentaje del salario del CEO	25.9%
Permanencia del CEO	36.3yrs
Participación del CEO	2.3%
Permanencia media de la dirección	5.7yrs
Promedio de permanencia en la Junta Directiva	17.3yrs

Actualizaciones recientes de la dirección

Recent updates

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Oct 25

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price

Aug 07

Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet

Jul 17

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Apr 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Leonard Schleifer en comparación con los beneficios de Regeneron Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$4b
Sep 30 2023	n/a	n/a	US$4b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$7m	US$2m	US$4b
Sep 30 2022	n/a	n/a	US$5b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$6m	US$2m	US$8b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$135m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$21m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$27m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$27m	US$1m	US$1b

CEO

Leonard Schleifer (70 yo)

36.3yrs

Permanencia

US$7,004,069

Compensación

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Leonard Schleifer	Co-Founder	36.3yrs	US$7.00m	2.25% $ 2.2b
George Yancopoulos	Co-Founder	23.3yrs	US$6.59m	1.22% $ 1.2b
Andrew Murphy	Executive Vice President of Research	5.3yrs	US$9.12m	0.049% $ 46.9m
Daniel Van Plew	Executive VP and GM of Industrial Operations & Product Supply	16yrs	US$8.85m	0.031% $ 30.1m
Marion McCourt	Executive Vice President of Commercial	6.2yrs	US$6.90m	0.012% $ 11.9m
Christopher Fenimore	Senior VP of Finance & CFO	3.3yrs	sin datos	0.023% $ 21.8m
Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	4.3yrs	sin datos	sin datos
Bob McCowan	Senior VP of IT & Chief Information Officer	3.3yrs	sin datos	sin datos
Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	no data	sin datos	sin datos
Joseph LaRosa	Executive VP	12.6yrs	US$7.13m	0.037% $ 35.9m
Melissa Lozner	Senior VP & Chief Compliance Officer	1.3yrs	sin datos	sin datos
Christina Chan	Senior Vice President of Corporate Affairs	no data	sin datos	sin datos

5.7yrs

Permanencia media

63yo

Promedio de edad

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Leonard Schleifer	Co-Founder	36.3yrs	US$7.00m	2.25% $ 2.2b
George Yancopoulos	Co-Founder	23.3yrs	US$6.59m	1.22% $ 1.2b
Christine Poon	Lead Independent Director	13.4yrs	US$720.03k	0.00074% $ 708.3k
Arthur Ryan	Independent Director	21.3yrs	US$725.03k	0.017% $ 16.2m
Michael Brown	Independent Director	32.8yrs	US$725.03k	0.012% $ 11.2m
Joseph Goldstein	Independent Director	32.8yrs	US$710.03k	0.0046% $ 4.5m
George Sing	Independent Director	36.3yrs	US$720.03k	0.027% $ 25.4m
N. Coles	Independent Director	7.3yrs	US$705.03k	0.000010% $ 9.6k
Craig Thompson	Independent Director	1.5yrs	US$1.02m	0.00042% $ 402.0k
Huda Zoghbi	Independent Director	7.6yrs	US$715.03k	0% $ 0
Bonnie Bassler	Independent Director	7.6yrs	US$715.03k	0.0013% $ 1.2m
Kathryn Guarini	Independent Director	less than a year	sin datos	sin datos

17.3yrs

Permanencia media

70yo

Regeneron Pharmaceuticals Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Executive Vice President of Research exercised options and sold US$11m worth of stock

Co-Founder exercised options and sold US$68m worth of stock

Insider exercised options and sold US$14m worth of stock

Insider recently sold US$7.6m worth of stock

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Recent updates

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Co-Founder exercised options and sold US$68m worth of stock

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider exercised options and sold US$14m worth of stock

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Insider recently sold US$7.6m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Independent Director notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Senior VP notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Executive Vice President of Research exercised options and sold US$11m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Announces Clinical Data from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal Pivotal Pulsar Trial Investigating Eylea Hd (Aflibercept) Injection 8 Mg with 12-Week Dosing Regimens

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma for Priority Review

Regeneron Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Board Changes

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. Announces Two-Year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-Related Macular Degeneration

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal PHOTON Trial Investigating Aflibercept 8 mg with 12- and 16-Week Dosing Regimens

Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet

Regeneron Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

FDA Issues Complete Response Letter (CRL) for Aflibercept 8 Mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings At A Third-Party Filler

Executive Vice President of Commercial notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. Provides Updated Data from Two Phase 2 Expansion Dose Cohorts Evaluating Investigational Linvoseltamab

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

Now 21% undervalued

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Now 21% undervalued

Senior VP notifies of intention to sell stock

Now 20% undervalued after recent price drop

Chairman of the Board exercised options and sold US$14m worth of stock

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approved Eylea Injection

Senior VP exercised options and sold US$1.7m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Análisis de compensación del CEO